Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods

Table 6 Insulin sensitivity indices in Group IV

Time	0 mo (mean ± SE)	6 mo (mean ± SE)	P value
FPI (uU/mL)	14.1 ± 4.3	18.2 ± 4.3	0.525
HOMA-IR%	4.6 ± 1.5	4.9 ± 1.2	0.895
HOMA-B%	77.8 ± 22.4	91.7 ± 14.6	0.618
Fasting C-peptide (ng/mL)	1.1 ± 0.2	1.5 ± 0.4	0.287
Stimulated C-peptide (ng/mL)	2.1 ± 0.3	2.8 ± 0.8	0.408

HOMA-IR: Homeostasis model assessment insulin resistance index; HOMA-B: Homeostasis model assessment beta cell function.